Our results show the potential of in vivo liver MRI and 1H‐MRS to noninvasively diagnose and stage the progression of NAFLD and to monitor treatment response in an eNOS−/− murine model that represents the classic NAFLD phenotype associated with metabolic syndrome. This evidence concerns the gene NOS3 and metabolic dysfunction-associated steatotic liver disease.